| 10.9 1.73 (18.87%) | 01-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.56 | 1-year : | 15.74 |
| Resists | First : | 11.61 | Second : | 13.47 |
| Pivot price | 10.9  |
|||
| Supports | First : | 8.6 | Second : | 7.15 |
| MAs | MA(5) : | 9.62 |
MA(20) : | 11.06 |
| MA(100) : | 11.25 |
MA(250) : | 8.12 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 27.4 |
D(3) : | 18 |
| RSI | RSI(14): 50.2 |
|||
| 52-week | High : | 13.56 | Low : | 3.34 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CTNM ] has closed above bottom band by 49.9%. Bollinger Bands are 82.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.98 - 11.03 | 11.03 - 11.07 |
| Low: | 9.05 - 9.1 | 9.1 - 9.15 |
| Close: | 10.81 - 10.9 | 10.9 - 10.99 |
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
Thu, 11 Dec 2025
Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering - Business Wire
Thu, 11 Dec 2025
Contineum Therapeutics launches $75 million public offering of stock - Investing.com
Thu, 11 Dec 2025
Contineum Therapeutics Announces Proposed $75.0 Million Public Offering - Business Wire
Mon, 24 Nov 2025
Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference - Business Wire
Thu, 30 Oct 2025
Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 30 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 58 (%) |
| Shares Short | 1,700 (K) |
| Shares Short P.Month | 1,190 (K) |
| EPS | -2.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.17 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.9 % |
| Return on Equity (ttm) | -30.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.23 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -52 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | -4.85 |
| PEG Ratio | 0 |
| Price to Book value | 1.76 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.33 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|